A. De Caluwé , X. Catteau , Z. Denis , M. Carausu , I. Desmoulins , E. Romano , V. Remouchamps , A. Baten , P. Poortmans , C. Van Marcke , F. Rothé , M. Ignatiadis , M. Piccart , D. Larsimont , J. Stagg , C. Sotiriou , R.F. Salgado , L. Buisseret
{"title":"随机Neo-CheckRay II期试验评估新辅助免疫放疗和腺苷途径阻断治疗早期、高风险ER+/HER2-乳腺癌(BC)的2O TILs和PD-L1早期动态","authors":"A. De Caluwé , X. Catteau , Z. Denis , M. Carausu , I. Desmoulins , E. Romano , V. Remouchamps , A. Baten , P. Poortmans , C. Van Marcke , F. Rothé , M. Ignatiadis , M. Piccart , D. Larsimont , J. Stagg , C. Sotiriou , R.F. Salgado , L. Buisseret","doi":"10.1016/j.iotech.2024.100886","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100886"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"2O TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC)\",\"authors\":\"A. De Caluwé , X. Catteau , Z. Denis , M. Carausu , I. Desmoulins , E. Romano , V. Remouchamps , A. Baten , P. Poortmans , C. Van Marcke , F. Rothé , M. Ignatiadis , M. Piccart , D. Larsimont , J. Stagg , C. Sotiriou , R.F. Salgado , L. Buisseret\",\"doi\":\"10.1016/j.iotech.2024.100886\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":73352,\"journal\":{\"name\":\"Immuno-oncology technology\",\"volume\":\"24 \",\"pages\":\"Article 100886\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immuno-oncology technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590018824001837\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-oncology technology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590018824001837","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
2O TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC)